<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900653</url>
  </required_header>
  <id_info>
    <org_study_id>4-2009-0022</org_study_id>
    <nct_id>NCT00900653</nct_id>
  </id_info>
  <brief_title>Low Dose Estriol With Lactobacilli Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women</brief_title>
  <official_title>Low Dose Estriol With Lactobacilli (Gynoflor) Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized, Open, Parallel-Group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recurrent urinary tract infections (UTI) are a problem for postmenopausal women. The aim of&#xD;
      this trial is to evaluate the effectiveness of lactobacilli in combination with low dose&#xD;
      estriol for preventing recurrent urinary tract infections in postmenopausal women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Anticipated">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of urinary tract infection</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>vaginal pH</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lactobacillus colonization</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Gynoflor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gynoflor E (low dose estriol with lactobacillus)</intervention_name>
    <description>The medication, in the form of one vaginal tablet, is administered in the evenings for 18 days</description>
    <arm_group_label>Gynoflor</arm_group_label>
    <other_name>Gynoflor E vaginal tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal woman&#xD;
&#xD;
          -  History of urinary tract infection&#xD;
&#xD;
          -  Agree to abstain from self-medication with antibiotics for UTI symptoms&#xD;
&#xD;
          -  Agree to abstain from the use of any other intra-vaginal product&#xD;
&#xD;
          -  Capable of providing informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ovarian cancer, cervical cancer, breast cancer&#xD;
&#xD;
          -  Estrogen treatment within last 2 years&#xD;
&#xD;
          -  Vaginal bleeding&#xD;
&#xD;
          -  Antibiotic therapy fewer than three days prior to randomization visit&#xD;
&#xD;
          -  Known congenital urologic or gynecologic abnormalities&#xD;
&#xD;
          -  Indwelling urinary catheter&#xD;
&#xD;
          -  Thromboembolic disease&#xD;
&#xD;
          -  Uncompensated liver disease&#xD;
&#xD;
          -  Immunosuppressive drug within 60 days&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>May 12, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <last_update_submitted>May 29, 2009</last_update_submitted>
  <last_update_submitted_qc>May 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jun Yong Choi</name_title>
    <organization>Yonsei University College of Medicine</organization>
  </responsible_party>
  <keyword>urinary tract infections</keyword>
  <keyword>postmenopause</keyword>
  <keyword>lactobacillus</keyword>
  <keyword>estriol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

